<DOC>
	<DOCNO>NCT01982747</DOCNO>
	<brief_summary>MGN1703 develop use treat cancerous tumor effect colon , skin , kidneys lung . The dosage form MGN1703 investigation injection . The goal study evaluate effect MGN1703 electrical activity heart healthy subject look general safety .</brief_summary>
	<brief_title>A Phase I Study Assess Cardiac General Safety Pharmacokinetics 60 mg MGN1703</brief_title>
	<detailed_description />
	<criteria>1 . The subject sign IRB/IECapproved inform consent prior studyrelated procedure . 2 . Subject male female le 6 subject per sex study . 3 . Subject 18 65 year age . 4 . Subject 's BMI â‰¤32 kg/m2 . 5 . Female subject childbearing potential must pregnant lactate negative serum HCG pregnancy test result Screening negative urine HCG pregnancy test result Days 1 14 prior receive study medication . 6 . Female subject childbearing potential male subject must use adequate method contraception Screening completion study . Acceptable method contraception barrier method ( male condom , female condom , diaphragm , cervical cap , spermicide IUD ) , surgical sterility ( documented doctor 's report vasectomy , hysterectomy and/or bilateral oophorectomy ) and/or postmenopausal status ( define least 1 year without menses demonstrate medical history subject report ) . 7 . Subject good health determine vital sign , medical history , physical exam , safety laboratory analyse Screening study . 1 . Subject use investigational product within 30 day prior screen study . 2 . Subject use prescription nonprescription drug ( include vitamin , mineral , herbal/plantderived preparation ) within 2 week Screening ( exclude oral contraceptive , hormonal IUD , hormone replacement therapy acetaminophen ) unless deem acceptable Investigator consultation Sponsor . 3 . Subject positive drug and/or alcohol test Screening , Day 1 Day 14 . 4 . The subject history drug alcohol abuse within 2 year Screening . 5 . The subject unable abstain ingest alcohol , caffeine , grapefruit Grapefruit juice 72 hour prior dose . 6 . The subject clinically significant history cardiovascular , endocrinologic , hematologic , hepatic , immunologic , metabolic , urologic , pulmonary , neurologic , dermatologic , psychiatric , renal , and/or major disease malignancy . 7 . Subject history cardiac disease risk factor TdP include ( limited ) unexplained syncope , cardiac arrest , unexplained cardiac arrhythmia , structural heart disease family history Long QT syndrome . 8 . Subject evidence follow cardiac conduction abnormality Screening , Day 1 Day 1 prior receive study medication : 1 . QTcF interval &gt; 430 msec male &gt; 450 msec female 2 . PR interval &gt; 240 msec &lt; 110 msec 3 . Evidence second thirddegree AVB 4 . Electrocardiographic evidence complete LBBB , complete RBBB incomplete LBBB 5 . Intraventricular conduction delay QRS duration &gt; 120 msec 6 . Heart rate &lt; 40 bpm &gt; 90 bpm 7 . Pathological Q wave ( define &gt; 40 msec depth &gt; 0.40.5 mV ) 8 . Evidence ventricular preexcitation 9 . The safety laboratory analyse Screening outside normal limit consider Investigator clinically significant . 10 . Any acute chronic condition , opinion Investigator , would limit subject 's ability complete and/or participate clinical study , history noncompliance medical regimen , subject consider potentially unreliable . 1 . The subject positive test result HIV antibody . 2 . The subject positive test result hepatitis C antibody HBsAg .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>Cardiac Safety</keyword>
	<keyword>General Safety</keyword>
	<keyword>Pharmacokinetics</keyword>
</DOC>